Lemaitre Vascular (LMAT) Total Non-Current Liabilities (2010 - 2026)
Lemaitre Vascular (LMAT) reported Total Non-Current Liabilities of $221.6 million for Q1 2026, up 6.76% year-over-year from $207.6 million in Q1 2025, and little changed quarter-over-quarter from $221.7 million in Q4 2025.
Lemaitre Vascular (LMAT) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Lemaitre Vascular (LMAT) has 17 years of Total Non-Current Liabilities data on file, last reported at $221.6 million in Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $221.6 million, up 6.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $221.6 million (up 6.76% YoY), and the FY2025 annual result was $221.7 million, up 3.61% from the prior year.
- Total Non-Current Liabilities was little changed at $221.6 million in Q1 2026 per LMAT's latest filing, from $221.7 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $221.7 million in Q4 2025 and troughed at $33.9 million in Q1 2022.
- A 5-year average of $103.2 million and a median of $43.3 million in 2024 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities plunged 50.93% in 2022, then soared 395.54% in 2025.
- A 5-year view of Total Non-Current Liabilities shows it stood at $42.1 million in 2022, then advanced by 10.72% to $46.6 million in 2023, then jumped by 359.03% to $214.0 million in 2024, then gained by 3.61% to $221.7 million in 2025, then dropped by 0.03% to $221.6 million in 2026.
- Business Quant data shows LMAT's Total Non-Current Liabilities at $221.6 million in Q1 2026, $221.7 million in Q4 2025, and $218.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn | 1.91 Bn |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn | 24.24 Bn |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn | 17.13 Bn |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn | 941.16 Mn |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn | 1.03 Bn |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn | 8.65 Bn |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn | 3.98 Bn |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn | 2.10 Bn |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn | 12.54 Bn |
| 10 | Lemaitre Vascular | 2.12 Bn | 1.75 Bn | 48.40 Mn | 221.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 221.59 Mn |
| Dec 31, 2025 | 221.67 Mn |
| Sep 30, 2025 | 218.54 Mn |
| Jun 30, 2025 | 214.59 Mn |
| Mar 31, 2025 | 207.56 Mn |
| Dec 31, 2024 | 213.96 Mn |
| Sep 30, 2024 | 45.32 Mn |
| Jun 30, 2024 | 43.31 Mn |
| Mar 31, 2024 | 43.28 Mn |
| Dec 31, 2023 | 46.61 Mn |
| Sep 30, 2023 | 43.23 Mn |
| Jun 30, 2023 | 42.06 Mn |
| Mar 31, 2023 | 40.07 Mn |
| Dec 31, 2022 | 42.10 Mn |
| Sep 30, 2022 | 38.40 Mn |
| Jun 30, 2022 | 38.89 Mn |
| Mar 31, 2022 | 33.90 Mn |
| Dec 31, 2021 | 35.95 Mn |
| Sep 30, 2021 | 39.67 Mn |
| Jun 30, 2021 | 56.12 Mn |